> Diabetes Research > Osteoporosis Risk in Avandia

Osteoporosis Risk in Avandia

Posted on February 19, 2018 | No Comments on Osteoporosis Risk in Avandia

The diabetes drug, rosiglitazone (Avandia) may increase risk for bone thinning or osteoporosis, which could help explain why diabetics may have an increased risk of fractures. The study found that the drug increased the activity of the cells that degrade bones in mice; according to results published online in Nature Medicine. GlaxoSmithKline, the company that markets the drug, has already acknowledged that a study has found that there is a higher risk of fractures among women who take Avandia.

“The study has led to a better understanding of the challenges associated with long-term treatment of patients with type 2 diabetes;’ said lead author, Ronald M. Evans of the Salk Institute for Biological Studies in La Jolla, California. He added that the discovery could provide for the development of a “next generation” drug that can specifically address this side effect and other matters dealing with bone physiology. The research was funded by the Howard Hughes Medical Institute and the National Institutes of Health.

Related Posts:

» Tags: ,

Leave a Reply

Your email address will not be published. Required fields are marked *